Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.

Schmidt, Ralph; Majer, Istvan; García Román, Natalia; Rivas Basterra, Alejandra; Grubb, ElizaBeth; Medrano López, Constancio

Schmidt, Ralph; Majer, Istvan; García Román, Natalia; Rivas Basterra, Alejandra; Grubb, ElizaBeth; Medrano López, Constancio.

Afiliación

Schmidt R; Pharmerit International, Health Economics and Outcomes Research, Zimmerstraße 55, 10117, Berlin, Germany. rschmidt@pharmerit.com.
Majer I; Pharmerit International, Health Economics and Outcomes Research, Rotterdam, the Netherlands.
García Román N; AbbVie, Medical Department, Madrid, Spain.
Rivas Basterra A; AbbVie, Government Affairs and Market Access, Madrid, Spain.
Grubb E; AbbVie, Health Economics and Outcomes Research, Chicago, IL, USA.
Medrano López C; Pediatric Cardiology, Gregorio Marañón University Hospital, Madrid, Spain.

Health Econ Rev ; 7(1): 47, 2017 Dec 19.

Article en En | MEDLINE | ID: mdl-29260345

Palabras clave

Congenital heart disease; Cost-effectiveness; Palivizumab; Prophylaxis; Respiratory syncytial virus; Spain

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Health Econ Rev Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google